Nancy A. Melville

News

Selenium Supplementation Shows Thyroid Benefits

Author:: Nancy A. Melville

Publish date: February 20, 2024

Systematic review suggests selenium supplements may help patients with Hashimoto thyroiditis.

News

CAR T-Cell: Do Benefits Still Outweigh Risks?

Author:: Nancy A. Melville

Publish date: February 14, 2024

“Cautious reassurance” urged, as early reports suggest that the risks of secondary malignancies are similar to those of other cancer treatments.

News

Testosterone Replacement Shows No Benefit in Diabetes Prevention

Author:: Nancy A. Melville

Publish date: February 9, 2024

The study showed that the only major indication for testosterone replacement therapy is to treat symptoms of hypogonadism.

News

SGLT2 Inhibitors Reduce Kidney Stone Risk in Type 2 Diabetes

Author:: Nancy A. Melville

Publish date: February 7, 2024

Patients with T2DM who are treated with SGLT2 inhibitors have reduced risk of kidney stones, according to study.

News

Stockholm3 Prostate Test Bests PSA for Prostate Cancer Risk in North America

Author:: Nancy A. Melville

Publish date: January 30, 2024

The Stockholm3 blood test, using a multiplex algorithm, shows benefits over PSA in a diverse, multi-ethnic cohort beyond a Swedish population cohor...

News

ctDNA Clearance Improves Prediction of Relapse Risk in Urothelial Cancer

Author:: Nancy A. Melville

Publish date: January 29, 2024

The combination of ctDNA with other biomarkers shows further benefits in predicting treatment response.

News

T-ALL: Cranial Radiotherapy Yields Little Benefit

Author:: Nancy A. Melville

Publish date: January 23, 2024

Comparisons of T-ALL cohorts show similar outcomes, with or without radiotherapy.

News

Are Post-Meal Insulin Surges Beneficial?

Author:: Nancy A. Melville

Publish date: January 5, 2024

Rapid surges in insulin following a meal are associated with favorable long-term cardiometabolic benefits, including improvements in beta cell func...

News

ALL: Asparaginase Tx Boosts Survival in AYA Patients

Author:: Nancy A. Melville

Publish date: December 22, 2023

Intensive C10403 regimen showed “very encouraging” improvements in event-free, overall survival in teenagers and young adults with ALL.

News

Children who are overweight at risk for chronic kidney disease

Author:: Nancy A. Melville

Publish date: December 13, 2023

“Given the increasing obesity rates among adolescents, our findings are a harbinger of the potentially preventable increasing burden of CKD and sub...

News

Anti-Rheumatic Drugs Linked to Reduced Thyroid Disease Incidence

Author:: Nancy A. Melville

Publish date: December 12, 2023

In a large Swedish rheumatoid arthritis cohort, the incidence of thyroid disease declines after RA diagnosis vs. the general population, with the e...

News

Myeloma: Isatuximab Four-Drug Regimen Boosts MRD Negativity

Author:: Nancy A. Melville

Publish date: December 11, 2023

Quadruplet regimen with anti-CD38 drug isatuximab improved MRD negativity vs. the standard triplet regimen in newly diagnosed myeloma patients.

News

Telemedicine in diabetes care associated with worse outcomes

Author:: Nancy A. Melville

Publish date: December 11, 2023

Patients receiving telemedicine-only care had no significant changes or improvements in adjusted A1c whereas those receiving in-person care had a s...

News

Relapsed DLBCL: With Complete Interim Response, SCT Outperforms CAR T

Author:: Nancy A. Melville

Publish date: December 11, 2023

Awaiting CAR T therapy, patients with complete response to interim chemo show better outcomes with subsequent autologous transplantation, compared ...

News

Most stop taking weight loss drugs within 1 year

Author:: Nancy A. Melville

Publish date: December 7, 2023

Those with higher weight loss at 6 months had a higher likelihood of remaining on the weight loss medication at 1 year.